VEGFA and non-small cell lung carcinoma: Bevacizumab, which is a monoclonal antibody targeting circulating VEGF, was the first angiogenesis inhibitor approved for treatment of advanced NSCLC, though its use is limited to non-squamous histology in first-line treatment.